These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 24802131)

  • 1. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.
    De Vita S; Quartuccio L; Salvin S; Picco L; Scott CA; Rupolo M; Fabris M
    Clin Exp Rheumatol; 2014; 32(4):490-4. PubMed ID: 24802131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome.
    Pontarini E; Fabris M; Quartuccio L; Cappeletti M; Calcaterra F; Roberto A; Curcio F; Mavilio D; Della Bella S; De Vita S
    Rheumatology (Oxford); 2015 Aug; 54(8):1429-34. PubMed ID: 25740829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rituximab therapy for systemic manifestations and MALT lymphomas of the parotid gland in Sjögren's disease: preliminary data].
    Logvinenko OA; Vasil'ev VI; Sedyshev SKh; Safonova TN; Rodionova EB; Kokosadze NV; Aleksandrova EN; Cherkasova MV; Radenska-Lopovok SG; Nasonov EL
    Ter Arkh; 2012; 84(12):88-96. PubMed ID: 23479998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
    Pijpe J; van Imhoff GW; Spijkervet FK; Roodenburg JL; Wolbink GJ; Mansour K; Vissink A; Kallenberg CG; Bootsma H
    Arthritis Rheum; 2005 Sep; 52(9):2740-50. PubMed ID: 16142737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren's syndrome: results of the BELISS study.
    Seror R; Nocturne G; Lazure T; Hendel-Chavez H; Desmoulins F; Belkhir R; Ravaud P; Benbijja M; Poirier-Colame V; Taoufik Y; Mariette X
    Arthritis Res Ther; 2015 Sep; 17(1):241. PubMed ID: 26336930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome.
    Cornec D; Costa S; Devauchelle-Pensec V; Jousse-Joulin S; Marcorelles P; Berthelot JM; Chiche L; Hachulla E; Hatron PY; Goeb V; Vittecoq O; Saraux A; Pers JO
    J Autoimmun; 2016 Feb; 67():102-110. PubMed ID: 26688003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study.
    De Vita S; Quartuccio L; Seror R; Salvin S; Ravaud P; Fabris M; Nocturne G; Gandolfo S; Isola M; Mariette X
    Rheumatology (Oxford); 2015 Dec; 54(12):2249-56. PubMed ID: 26242856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.
    Seror R; Sordet C; Guillevin L; Hachulla E; Masson C; Ittah M; Candon S; Le Guern V; Aouba A; Sibilia J; Gottenberg JE; Mariette X
    Ann Rheum Dis; 2007 Mar; 66(3):351-7. PubMed ID: 16950808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double anti-B cell and anti-BAFF targeting for the treatment of primary Sjögren's syndrome.
    Gandolfo S; De Vita S
    Clin Exp Rheumatol; 2019; 37 Suppl 118(3):199-208. PubMed ID: 31464677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
    Lenert A; Lenert P
    Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacity of a sequential treatment by anti-CD 20 monoclonal antibody and belimumab in type II cryoglobulinaemia associated with primary Sjögren syndrome refractory to rituximab alone.
    Chevalier K; Belkhir R; Seror R; Mariette X; Nocturne G
    Ann Rheum Dis; 2020 Sep; 79(9):1257-1259. PubMed ID: 32398282
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjögren's syndrome: follow-up after the end of the phase II open-label BELISS study.
    Quartuccio L; Salvin S; Corazza L; Gandolfo S; Fabris M; De Vita S
    Clin Exp Rheumatol; 2016; 34(2):311-4. PubMed ID: 26886154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.
    Pers JO; Devauchelle V; Daridon C; Bendaoud B; Le Berre R; Bordron A; Hutin P; Renaudineau Y; Dueymes M; Loisel S; Berthou C; Saraux A; Youinou P
    Arthritis Rheum; 2007 May; 56(5):1464-77. PubMed ID: 17469105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma.
    Pijpe J; van Imhoff GW; Vissink A; van der Wal JE; Kluin PM; Spijkervet FK; Kallenberg CG; Bootsma H
    Ann Rheum Dis; 2005 Jun; 64(6):958-60. PubMed ID: 15576414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren's syndrome: a retrospective clinical study.
    Pollard RP; Pijpe J; Bootsma H; Spijkervet FK; Kluin PM; Roodenburg JL; Kallenberg CG; Vissink A; van Imhoff GW
    J Rheumatol; 2011 Oct; 38(10):2198-208. PubMed ID: 21844152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab therapy in primary Sjögren's syndrome.
    Alcântara C; Gomes MJ; Ferreira C
    Ann N Y Acad Sci; 2009 Sep; 1173():701-5. PubMed ID: 19758218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study.
    Mariette X; Seror R; Quartuccio L; Baron G; Salvin S; Fabris M; Desmoulins F; Nocturne G; Ravaud P; De Vita S
    Ann Rheum Dis; 2015 Mar; 74(3):526-31. PubMed ID: 24347569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to rituximab therapy and local BAFF overexpression in Sjögren's syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma.
    Quartuccio L; Fabris M; Moretti M; Barone F; Bombardieri M; Rupolo M; Lombardi S; Pitzalis C; Beltrami CA; Curcio F; De Vita S
    Open Rheumatol J; 2008; 2():38-43. PubMed ID: 19088870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production.
    Lavie F; Miceli-Richard C; Ittah M; Sellam J; Gottenberg JE; Mariette X
    Ann Rheum Dis; 2007 May; 66(5):700-3. PubMed ID: 17040963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of retreatment with rituximab in patients with primary Sjögren's syndrome.
    Meiners PM; Arends S; Meijer JM; Moerman RV; Spijkervet FK; Vissink A; Bootsma H
    Clin Exp Rheumatol; 2015; 33(3):443-4. PubMed ID: 25897541
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 30.